Online Appendix 1. Author Relationships With Industry and Other Entities (COMPREHENSIVE)—2017 Focused Update for the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk and the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald M. Lloyd-Jones <em>(Chair)</em></td>
<td>Northwestern University—Chair, Department of Preventive Medicine; Senior Associate Dean for Clinical and Translational Research; Director, Northwestern University Clinical and Translational Sciences Institute</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● American Heart Association*</td>
<td>None</td>
</tr>
</tbody>
</table>
| Pamela Bowe Morris *(Vice-Chair)* | Medical University of South Carolina—Associate Professor of Medicine, Division of Cardiology | • Amgen  
• AstraZeneca  
• Sanofi  
• Regeneron | None | None | ● Amgen | None | None |
| Christie M. Ballantyne | Baylor College of Medicine and Methodist DeBakey Heart & Vascular Center—Professor of Medicine; Professor of Genetics; Chief, Cardiovascular Research Section | ● Abbott Diagnostic  
● Amarin  
● Amgen  
● Arena†  
● AstraZeneca†  
● Boehringer Ingelheim†§  
● Eli Lilly  
● Esperion  
● Genzyme  
● Ionis§  
● Matinas BioPharma  
● Merck†  
● Novartis  
● Pfizer†  
● Regeneron | None | None | ● Abbott Diagnostic†  
● Amarin†  
● American Diabetes Association†  
● Amgen†  
● Eli Lilly†  
● Esperion†  
● GlaxoSmithKline†  
● Ionis†§  
● National Institutes of Health†  
● Novartis†  
● Otsuka†  
● Pfizer†  
● Regeneron†  
● Roche Diagnostic†  
● Sanofi- | ● American Heart Association†  
● Roche* | None |
<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim K. Birtcher</td>
<td>University of Houston College of Pharmacy—Clinical Professor</td>
<td>• Roche Diagnostics</td>
<td>None</td>
<td>None</td>
<td>Synthelabo†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sondra M. DePalma</td>
<td>Penn State Hershey Medical Center—Assistant Director of Advanced Practice and Physician Assistant</td>
<td>• American Society of Hypertension</td>
<td>None</td>
<td>None</td>
<td>• Accreditation Council for Clinical Lipidology*§</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David D. Daly Jr.</td>
<td>Medical University of South Carolina—Cardiology Fellow</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Margo B. Minissian</td>
<td>Cedars-Sinai Heart Institute, Barbara Streisand Women’s Heart Center—Nurse Scientist, Clinical Lipid Specialist</td>
<td>• Preventive Cardiology Nurses Association</td>
<td>None</td>
<td>• Valet Services*</td>
<td>• American Heart Association†</td>
<td>Gilead†</td>
<td>None</td>
</tr>
<tr>
<td>Carl E. Orringer</td>
<td>University of Miami Miller School of Medicine—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• National Institutes of Health†</td>
<td>• National Lipid Foundation</td>
<td>None</td>
</tr>
<tr>
<td>Sidney C. Smith Jr.</td>
<td>University of North Carolina Center for Cardiovascular Science and Medicine—Professor of Medicine and Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• National Lipid Association†</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.
* No financial benefit.
† Significant relationship.
‡ Relationship during development of 2016 Pathway but not during development of 2017 Focused Update.